PEGASYS Trademark

Trademark Overview

On Wednesday, June 2, 2021, a trademark application was filed for PEGASYS with the United States Patent and Trademark Office. The USPTO has given the PEGASYS trademark a serial number of 79314220. The federal status of this trademark filing is REGISTERED as of Tuesday, August 2, 2022. This trademark is owned by pharma& Schweiz GmbH. The PEGASYS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for the treatment of hepatitis B and hepatitis C
pegasys

General Information

Serial Number79314220
Word MarkPEGASYS
Filing DateWednesday, June 2, 2021
Status700 - REGISTERED
Status DateTuesday, August 2, 2022
Registration Number6805591
Registration DateTuesday, August 2, 2022
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 17, 2022

Trademark Statements

Goods and ServicesPharmaceuticals for the treatment of hepatitis B and hepatitis C
Pseudo MarkPEGASUS SYSTEM

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, June 28, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party Namepharma& Schweiz GmbH
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressCH
Party Namepharma& Schweiz GmbH
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressCH
Party Namepharma& Schweiz GmbH
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCH

Trademark Events

Event DateEvent Description
Saturday, April 29, 2023CHANGE OF NAME/ADDRESS REC'D FROM IB
Sunday, November 27, 2022FINAL DECISION TRANSACTION PROCESSED BY IB
Wednesday, November 9, 2022FINAL DISPOSITION NOTICE SENT TO IB
Wednesday, November 9, 2022FINAL DISPOSITION PROCESSED
Wednesday, November 2, 2022FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, August 2, 2022NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, August 2, 2022REGISTERED-PRINCIPAL REGISTER
Tuesday, May 17, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 17, 2022PUBLISHED FOR OPPOSITION
Sunday, May 15, 2022NOTIFICATION PROCESSED BY IB
Wednesday, April 27, 2022NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, April 27, 2022NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, April 27, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sunday, April 10, 2022REFUSAL PROCESSED BY IB
Friday, April 8, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, April 5, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, April 4, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, April 4, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, March 22, 2022NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Monday, March 21, 2022REFUSAL PROCESSED BY MPU
Saturday, February 19, 2022NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, February 18, 2022NON-FINAL ACTION WRITTEN
Thursday, February 17, 2022ASSIGNED TO EXAMINER
Monday, August 30, 2021LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Saturday, August 28, 2021RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
Friday, July 2, 2021APPLICATION FILING RECEIPT MAILED
Monday, June 28, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, June 25, 2021SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB

Related Keywords

pegasys hepatitis treatment pharmaceuticals